XCancer

PET Imaging of Patients With Melanoma and Malignant Brain Tumors Using an 124I-labeled cRGDY Silica Nanomolecular Particle Tracer: A Microdosing Study

Description:

Current tests to detect cancer, including CAT scans and MRI scans, are limited. PET scans use special dyes that are injected into a vein and can better localize possible cancer. The investigators have developed a new particle that can carry a radioactive dye to a very specific area of the tumor. When using a PET scan the radioactive dye can be viewed in areas of possible disease. This particle has been studied in mice and was safe. The particles will not treat the cancer and any images or information found during this study will not be used for your treatment. The information collected may be used to guide the design of future studies to detect and/or treat tumors.

Sponsor:

Memorial Sloan Kettering Cancer Center

Phase:

N/A

Contacts:

Hilda Stambuk, MD (PRINCIPAL_INVESTIGATOR)

Government Study Link:

NCT01266096 - Click here to see study on

ClinicalTrials.gov

cRGDY-PEG-dots

Isotope(s):
Target(s):
  • αvβ3
Ligand Class: Peptides
Linker: PEG
Inclusion
  • Residual clinically or radiographically evident tumor, including primary cutaneous and mucosal melanomas or malignant brain tumor
  • Prior radiation therapy, chemotherapy, or surgery in patients requiring flap reconstruction in the head and neck region.
  • Newly-diagnosed or recurrent (local,regional, metastatic) metastatic melanoma or malignant brain tumor patients with
  • Histologically confirmed diagnosis of melanoma or malignant brain tumor at MSKCC
  • * 18 years of age or older
Exclusion
  • Allergic reaction to iodine-containing contrast material
  • Known pregnancy or breast-feeding.
  • Medical illness unrelated to the tumor which in the opinion of the attending physician and principal investigator will preclude administration of the tracer. This includes patients with uncontrolled infection, chronic renal insufficiency, myocardial infarction within the past 6 months, unstable angina, cardiac arrhythmias other than chronic atrial fibrillation and chronic active or persistent hepatitis, or New York Heart Association Classification III or IV heart disease.
  • History of any malignancy (excluding primary cancer for metastatic patients) other than melanoma or malignant brain tumors for which the disease-free interval is \<5 years.
  • * Abnormal thyroid function, such as untreated clinical diagnosis of hypothyroidism, hyperthyroidism, or other thyroid disease